Effects of Concurrent Chemoradiotherapy and Sequential Radiotherapy and Chemotherapy on Progression-free Survival in Patients with Non-small Cell Lung Cancer
BIE Zhi-xin, GUO Jun
National geriatrics center, Beijing Hospital, chief physician 100730
Abstract：【Objective】To analyze the effect of concurrent chemoradiotherapy and sequential chemoradiotherapy on progression free survival in patients with limited Non-small-cell Carcinoma (NSCLC) induced by chemotherapy. 【Methods】One hundred and eight patients with NSCLC in our hospital were selected as the research object, the patients were randomly divided into group A and group B, each group with 54 cases. The group A received concurrent chemotherapy, the group B was treated with sequential chemotherapy. The adverse reaction rate, the therapeutic effect, the median survival after three cycles of treatment and quality of life score index were compared with between the two groups of patients.【Results】1.The curative effect of the group A was much higher than that of the group B (P<0.05); 2.The median progression free survival in group A was significantly higher than that in group B (P<0.05); 3.The incidence of adverse reactions in the group A was significantly lower than that in the group B (P<0.05); 4. Before treatment, there was no significant difference in quality of life between the two groups (P>0.05). After the treatment of the three cycle, the quality of life score of the group A was significantly higher than that of the group B (P<0.05).【Conclusion】Concurrent chemoradiotherapy can significantly improve the quality of life of patients with NSCLC, which has less adverse reactions and higher quality of life scores.
[1] 王轶楠,赵郁,岳海淑等.同期放化疗对局部晚期非小细胞肺癌外周血基质金属蛋白酶2和转化生长因子β1的影响及其意义[J].肿瘤研究与临床,2014,26(9):620-623. [2] Liang-Chih Liu,Thomas Chang-Yao Tsao,et al.EGCG inhibits transforming growth factors-β-mediated epithelial-to-mesenchymal transition via the inhibition of smad2 and erkl/2 signaling pathways in nonsmall cell lung cancer cells[J].J Agric Food Chem,2012,60(39):9863-9873. [3] Katakami N,Tada H,Mitsudomi T,et al.A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)[J].Cancer: A J Am Cancer Society,2012,118(24):6126-6135. [4] Saito H,Nakagawa K,Takeda K,et al.Randomized phase II study of carboplatin-paclitaxel or gemcitabine- vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan thoracic oncology Group 0004[J].Am J Clin Oncol,2012,35(1):58-63. [5] 赵子粼,罗敏,黄梁艳,等.肺癌微波消融序贯瘤内放射免疫治疗与手术后辅助放化疗的随机对照研究[J].现代肿瘤医学,2013,21(8):1745-1747. [6] 郭磊,汪进良,钱海利,等.多西他赛、培美曲塞联合盐酸埃克替尼不同序贯用药时序及选择合理用药时机对非小细胞肺癌细胞的体外抑制作用[J].中国药物应用与监测,2015,12(3):147-150. [7] 姜勇,崔林,何学军,等.不能手术局部晚期非小细胞肺癌同步或序贯放化疗85例临床分析[J].现代肿瘤医学,2017,25(1):56-59. (本文编辑:王沪湘) [收稿日期] 2017-01-07
2017, Vol. 34 
